Zonegran for the Treatment of Weight Gain Associated With Psychotropic Medication Use: A Placebo-Controlled Trial

Tuscaloosa Research & Education Advancement Corporation

Status and phase

Completed

Phase 4

Conditions

Obesity

Treatments

Drug: Placebo

Drug: Zonegran

Study type

Interventional

Funder types

Other

Industry

Identifiers

NCT00203450

TREAC Zonegran for Weight Loss

Details and patient eligibility

About

The primary objective of this study is to compare the efficacy of zonisamide (Zonegran; 100mg - 400mg/day) and placebo as an adjunctive agent on lowering weight in subjects who have a body mass index (BMI) of >25 and are on a psychotropic medication with a known side effect of weight gain.

Full description

After the screening period, patients fulfilling entrance criteria will be randomized to 100mg of zonisamide or placebo in a 2:1 ratio respectively. Patients will be assessed at baseline and on Weeks 2, 4, 8, 12, and 16-post randomization for weight, side effects, and symptoms. Symptoms will be assessed by the Young Mania Rating Scale (YMRS), Brief Psychiatric Rating Scale (BPRS), Hamilton Depression Rating Scale (HAMD), Hamilton Rating Scale for Anxiety (HARS), and Self-report measures of general health and mental status at baseline, weeks 2, 4, 8, 12,and 16. At the conclusion of the study, patients will be tapered from the study medication and will return to their primary provider for continued treatment of their psychiatric condition.

Enrollment

20 patients

Sex

All

Ages

19 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Are men or women, between the ages of 19 and 65, inclusive
Have a diagnosis of any type of bipolar disorder or any type of psychotic disorder based on structured diagnostic interview (MINI).
Are currently outpatients or inpatients and taking a neuroleptic or mood stabilizer medication (listed below) for the past 6 months, and on a stable dose for the past 2 months.
Have a body mass index > 25.
No substance use disorder in the past 2 months (except for nicotine or caffeine).
Agree to not become pregnant during the study and agree to use an adequate method of birth control during the study such as a barrier method, hormonal contraceptive, or surgical sterilization (females only). All women of childbearing potential must have a negative pregnancy test before beginning study medication.
Are able to swallow the capsules whole
Are willing and able to follow Investigator instructions and study procedures, and report adverse events
Not currently actively suicidal or homicidal.
No use of topiramate within the last 6 months.
No medical contraindication to the use of zonisamide.

List of medications for inclusion criterion #3:

All conventional neuroleptics. All atypical neuroleptics except aripiprazole or ziprasidone. All forms of valproate. All forms of lithium. All forms of carbamazepine.

Exclusion criteria

Clinically significant renal or hepatic disease.
History of acute intermittent porphyria, glucose-6phosphate dehydrogenase deficiency or hemolytic anemia.
Allergy to zonisamide or sulfonamides.
Have clinically unstable cardiovascular, hepatic, renal, gastrointestinal, pulmonary, metabolic, endocrine, or other systemic disease
Have laboratory test results that, in the opinion of the Investigator, are clinically significant abnormalities
Require treatment with any medication (e.g., carbonic anhydrase inhibitors) that might interact adversely with, or obscure, the action of the study drug
Are pregnant or lactating (females only)
Have a history of nephrolithiasis
Refuse to give informed consent
Have previously enrolled in this study or previously been treated with zonisamide